Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4856 - Iron deficiency anaemia in oncology: an epidemiological prospective study.

Date

10 Sep 2017

Session

Poster display session

Presenters

Jérôme BARRIERE

Citation

Annals of Oncology (2017) 28 (suppl_5): v543-v567. 10.1093/annonc/mdx388

Authors

J. BARRIERE1, J. Ferrero2, B. Hoch3, R. Largillier4, C. Hebert2, D. Borchiellini2, P. Follana2, V. Mari2, L. Evesque5, E. Saada-Bouzid2, R. Schiappa6, V. Raimondi7, E. Chamorey6, J. Viotti6

Author affiliations

  • 1 Oncology, Polyclinic Saint Jean, 06800 - Cagnes-sur-Mer/FR
  • 2 Medical Oncology, Centre Antoine Lacassagne, 06189 - Nice/FR
  • 3 Medical Oncology, Centre Azuréen de Cancérologie, 6250 - Mougins/FR
  • 4 Medical Oncology, Centre Azuréen de Cancérologie, Mougins/FR
  • 5 Medical Oncology, Centre Antoine Lacassagne, 6189 - Nice/FR
  • 6 Biostatistics And Epidemiology Department, Centre Antoine Lacassagne, 6189 - Nice/FR
  • 7 Laboratory, Laboratoire Cerballiance, Nice/FR
More

Resources

Abstract 4856

Background

Anaemia in oncology is frequent, decreasing quality of life and prognosis. Its causes are multiples and still largely unknown, among them, iron deficiency (ID) is seldom studied. Associated with inflammatory syndrome, ID leads to the sequestration of iron in macrophage, making it unavailable for erythropoiesis. Prevalence of ID needs to be specified in oncology as it could be easily corrected by intravenous iron, avoiding use of EPO or blood transfusion and their side effects.

Methods

In this prospective, multicentre cohort study (NCT01968304), anaemia and ID were evaluated in patients with locally advanced or metastatic solid tumour and lymphoma newly diagnosed before starting a chemotherapy regimen. Blood samples were collected at the inclusion (week 0 - W0), 6 weeks (W6) and 12 weeks (W12) after. Prevalence was evaluated for both functional ID (FID) and absolute ID (AID) in the general population and according to the tumours location. ID was correlated with tumour response (RECIST criteria).

Results

129 patients were enrolled between 2013 and 2015. 119 had solid tumours (breast 36, colorectal 27, lung 28, prostate 12, others 16) and 10 had lymphomas (not shown).rnTable:

1556P

rnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrn
Location N (%)Anaemia N (%)Functional iron deficiency N (%)Absolute iron deficiency N (%)Functional ID associated with Anaemia N (%)
W0W6W12W0W6W12W0W6W12W0W6W12
Breast 36 (30)13 (36.1)20 (64.5)17 (63.0)15 (41.7)20 (64.5)2 (5.6)1 (3.2)2 (7.4)6 (16.7)11 (35.5)11 (35.5)9 (33.3)
Colorectal 27 (23)20 (74.1)16 (72.7)11 (68.8)14 (51.9)8 (36.4)5 (18.5)3 (13.6)2 (12.5)10 (37.0)10 (37.0)6 (27.3)5 (31.2)
Lung 28 (24)16 (57.1)22 (88.0)14 (93.3)13 (48.1)8 (32.0)1 (3.7)0 (0.0)0 (0.0)8 (29.6)8 (29.6)8 (32.0)4 (26.7)
Prostate 12 (10)9 (75.0)11 (91.7)9 (81.8)6 (50.0)3 (25.0)0 (0.0)0 (0.0)0 (0.0)4 (33.3)4 (33.3)2 (16.7)2 (18.2)
All solid tumours 119 (100)63 (52.9)75 (72.8)56 (71.8)62 (48.0)49 (43.0)9 (7.0)5 (4.0)4 (5.0)32 (26.9)32 (26.9)32 (31.1)23 (29.5)
rn

At W0, 62 patients (48%) had FID, 32 (26.9%) had FID associated with anaemia and 9 (7%) had AID. FID prevalence remains constant from W0 to W12, so as FID anaemia and AID. Also, ID incidence remains constant between W6, 17 (15.2%) and W12 10 (11.6%). Localization was not correlated with FID or FID anaemia but prevalence of AID is higher for colorectal tumours. ID (evaluated at W12) was significantly correlated (p = 0.04) with tumour response at W12, 51.2% of responders among patients with no ID versus only 33.3% among patients with ID.

rn

Conclusions

Our data confirm the high prevalence of ID in cancer patients. Localization is not correlated with the prevalence of ID whereas absolute ID is of higher rate in colorectal cancer. Also, ID at W12 without supplementation seems to be predictive of chemotherapy response.

Clinical trial identification

NCT01968304. Release date: October 1, 2013

Legal entity responsible for the study

Centre Antoine Lacassagne

Funding

Vifor Pharma France

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.